0000950170-23-058943.txt : 20231103 0000950170-23-058943.hdr.sgml : 20231103 20231103184933 ACCESSION NUMBER: 0000950170-23-058943 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231101 FILED AS OF DATE: 20231103 DATE AS OF CHANGE: 20231103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lyon Joseph Douglas CENTRAL INDEX KEY: 0001817838 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 231377752 MAIL ADDRESS: STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED STREET 2: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 ownership.xml 4 X0508 4 2023-11-01 false 0001088856 CORCEPT THERAPEUTICS INC CORT 0001817838 Lyon Joseph Douglas C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 false true false false Chief Accounting Officer true Common Stock 2023-11-01 4 M false 1023 11.35 A 6877 D Common Stock 2023-11-01 4 S false 1023 28.08 D 5854 D Common Stock 2023-11-02 4 M false 3977 11.35 A 9831 D Common Stock 2023-11-02 4 S false 3977 28.1102 D 5854 D Stock option (right to buy) 11.35 2023-11-01 4 M false 1023 0 D 2029-02-08 Common Stock 1023 53144 D Stock option (right to buy) 11.35 2023-11-02 4 M false 3977 0 D 2029-02-08 Common Stock 3977 49167 D Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $28.08 to $28.1244. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Fully exercisable. /s/ Joseph Douglas Lyon 2023-11-03